Skip to content

Clinical trials

Smoldering Multiple Myeloma trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Smoldering Multiple Myeloma Country / region: United States Clear all

71 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20043
20081
20094
20105
20114
20121
20132
20143
20153
20165
20176
20184
20193
20202
20215
20226
20236
20244
20251
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed22
Recruiting20
Active, not recruiting14
Terminated10
Withdrawn3
Unknown status2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Dana-Farber Cancer Institute10
National Cancer Institute (NCI)6
M.D. Anderson Cancer Center5
City of Hope Medical Center4
Janssen Research & Development, LLC4
Memorial Sloan Kettering Cancer Center3
University of Rochester3
Case Comprehensive Cancer Center2
Mayo Clinic2
Regeneron Pharmaceuticals2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Smoldering Multiple Myeloma71
Multiple Myeloma33
Monoclonal Gammopathy of Undetermined Significance25
Neoplasms, Plasma Cell12
Immunoglobulin Light-chain Amyloidosis4
Waldenstrom Macroglobulinemia4
Leukemia, Lymphocytic, Chronic, B-Cell3
Paraproteinemias3
Amyloidosis2
Hematologic Neoplasms2

Trials

Showing 1 to 25 of 71. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.